Tech Mahindra Records Profit Of Rs 1,339 Crore In September-Quarter
IT major Tech Mahindra recorded a meagre slide in its net profit for second quarter of the current fiscal, which stood at Rs 1,339 crore, one per cent down from Rs 1,353 crore recorded in the first quarter of 2021-22.
On a year-on-year basis though, the company's profit went up by 25.8 per cent from Rs 1,065 crore.
Revenue for the July-September quarter of the current fiscal stood at Rs 10,881 crore, 6.7 per cent higher than Rs 10,198 crore recorded in the April-June quarter of 2021-22.
On a year-on-year basis, the company's revenue was higher by an impressive 16.1 percent from Rs 9,372 crore reported in the same quarter last year.
Tech Mahindra's revenue from IT services were Rs 9,576 crore during the September-end period, rising by 6.2 per cent over Rs 9,016 crore registered in June-end quarter. On a year-on-year basis, it increased by 13.7 percent from Rs 8,419 crore.
Commenting on the company's results, managing director and CEO of the company C P Gurnani said, "We remain committed to delivering long-term sustainable and profitable growth for the company. We have witnessed strong traction across all key markets as we invest in our digital capabilities through strategic partnerships.”
Tech Mahindra also announced acquisitions of two companies - US-based Infostar LLC and London-based We Make Websites Limited (WMW), for $105 million and $13 million, respectively to strengthen its digital portfolio.
Infostar LLC is a digital product engineering company that offers end-to-end product and data quality assurance solutions.
WMW offers Shopify-focused e-commerce agency and has 43 employees in the UK and US. The company was acquired for 9.4 million pounds.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.